Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis

Epilepsia

Volumn 47, Issue 11, 2006, Pages 1841-1854

  Luszczki, Jarogniew J ^a   Ratnaraj, Neville ^b   Patsalos, Philip N ^b   Czuczwar, Stanislaw J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Clonazepam; Ethosuximide; Isobolographic analysis; Pharmacodynamic interactions; Pharmacokinetic interactions; Phenobarbital; Stiripentol; Valproate

Indexed keywords

CLONAZEPAM; ETHOSUXIMIDE; PENTETRAZOLE; PHENOBARBITAL; STIRIPENTOL; VALPROIC ACID;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR; CLONIC SEIZURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EXPERIMENTAL MOUSE; FUNCTION TEST; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOUSE; MUSCLE TONE; NEUROMUSCULAR FUNCTION; NEUROTOXICITY; NONHUMAN; PAIN; PAIN THRESHOLD; PASSIVE AVOIDANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THERMAL STIMULATION;

EID: 33750928057     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00825.x     Document Type: Article

References (65)

1. Backonja MM. (2002) Use of anticonvulsants for treatment of neuropathic pain. Neurology 59(5 suppl. 2):S14-S17.
2. Bebin M, Bleck TP. (1994) New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 48:153-171.
3. Berenbaum MC. (1989) What is synergy? Pharmacol Rev;41:93-141. Erratum in: (1990) Pharmacological Reviews 41:422.
4. Boissier JR, Tardy J, Diverres JC. (1960) Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med Exp (Basel) 3:81-84.
5. Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G. (2003) Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol 56:526-536.
6. Chiron C, Coppola G, Plouin P, Robain O, Renard F. (1993) Multifocal epilepsy in infancy: value of stiripentol-clonazepam combination. Epilepsia 34(suppl. 6):73.
7. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356:1638-1642.
8. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, van Rijn CM. (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364-1374.
9. Eddy NB, Leimbach D. (1953) Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 107:385-393.
10. Farwell J, Levy RH, Anderson G, Tor JA. (1992) Stiripentol shows promise in partial complex seizures in children. Epilepsia 33(suppl. 3):81.
11. Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. (1993) Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 34:305-311.
12. Gasior M, Ungard JT, Witkin JM. (1999) Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 290:1148-1156.
13. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34:608-611.
14. Greco WR, Bravo G, Parsons JC. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331-385.
15. Kellinghaus C, Dziewas R, Ludemann P. (2002) Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure 11:243-249.
16. Kerr BM, Martinez-Lage JM, Viteri C, Tor J, Eddy AC, Levy RH. (1991) Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia 32:267-274.
17. Kinloch RA, Cox PJ. (2005) New targets for neuropathic pain therapeutics. Expert Opin Ther Targets 9:685-698.
18. Kwan P, Brodie MJ. (2000a) Early identification of refractory epilepsy. N Engl J Med 342:314-319.
19. Kwan P, Brodie MJ. (2000b) Epilepsy after the first drug fails: substitution or add-on? Seizure 9:464-468.
20. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. (1984) Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 36:661-669.
21. Levy RH, Loiseau P, Guyot M. (1987) Effects of stiripentol on valproate plasma level and metabolism. Epilepsia 28:605.
22. Litchfield JT, Wilcoxon F. (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113.
23. Lockard JS, Levy RH, Rhodes PH, Moore DF. (1985) Stiripentol in acute/chronic efficacy tests in monkey model. Epilepsia 26:704-712.
24. Loiseau P, Levy RH, Houin G, Rascol O, Dordain G. (1990) Randomized double-blind, parallel, multicenter trial of stiripentol added to carbamazepine in the treatment of carbamazepine-resistant epilepsies: an interim analysis. Epilepsia 31:618-619.
25. Löscher W, Honack D, Fassbender CP, Nolting B. (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8:171-189.
26. Löscher W, Jäckel R, Müller F. (1989) Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur J Pharmacol 163:1-14.
27. Löscher W, Nolting B. (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 9:1-10.
28. Löscher W, Schmidt D. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181.
29. Löscher W, Wauquier A. (1996) Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res Suppl 11:61-65.
30. Luszczki JJ, Czuczwar SJ. (2003) Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res 56:27-42.
31. Luszczki JJ, Czuczwar SJ. (2004) Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedeberg's Arch Pharmacol 369:434-446.
32. Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ. (2003a) Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:489-499.
33. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, Czuczwar SJ. (2003b) Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:1003-1013.
34. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. (2005a) Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole- induced seizures in mice: an isobolographic analysis. Epilepsy Behav 7:639-651.
35. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. (2005c) Pharmacodynamic and pharmacokinetic interaction studies with loreclezole and felbamate, lamotrigine, topiramate and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia 46:344-355.
36. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. (2006) Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedeberg's Arch Pharmacol 373:169-181.
37. Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ. (2003c) Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 28:1817-1830.
38. Luszczki JJ, Wojcik-Cwikla J, Andres MM, Czuczwar SJ. (2005b) Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 30:958-973.
39. Mares P, Slamberova R. (2004) Biphasic action of vigabatrin on cortical epileptic after-discharges in rats. Naunyn-Schmiedeberg's Arch Pharmacol 369:305-311.
40. Martinez-Lage JM, Loiseau P, Levy RH, Gonzalez I, Strube E, Tor J, Blehaut H. (1984) Clinical antiepileptic efficacy of stiripentol in resistant partial epilepsies. Epilepsia 25:673.
41. Micheletti G, Vargnes M, Lannes B, Tor J, Marescaux A, Depaulis A, Warter JM. (1988) Effect of stiripentol on petit mal-like epilepsy in Wistar rats. Epilepsia 29:709.
42. Novak V, Kanard R, Kissel JT, Mendell JR. (2001) Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 11:357-361.
43. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365-385.
44. Patsalos PN, Perucca E. (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347-356.
45. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, Vincent J, Dulac O. (1999) Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 40:1618-1626.
46. Perucca E, Kupferberg HJ. (2002) Drugs in development. Drugs in early clinical development. In Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds). Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia, pp. 913-928.
47. Perucca E, Gram L, Avanzini G, Dulac O. (1998) Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39:5-17.
48. Perucca E. (1995) Pharmacological principles as a basis for polytherapy. Acta Neurol Scand (suppl. 162):31-34.
49. Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G. (1984) A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung 34:199-204.
50. Porreca F, Jiang Q, Tallarida RJ. (1990) Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 179:463-468.
51. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. (2006) Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-receptor channels. Epilepsia 47:704-716.
52. Renard F, Musial C, Tor J, Dulac O. (1993) Single-blind add-on trial of stiripentol in epileptic children. Epilepsia 34(suppl. 6):74.
53. Rey E, Tran A, d' Athis P, Chiron C, Dulac O, Vincent J, Pons G. (1999) Stiripentol potentiates clobazam in childhood epilepsy: a pharmacological study. Epilepsia 40(suppl. 7):112-113.
54. Schapel G, Chadwick D. (1996) Tiagabine and non-convulsive status epilepticus. Seizure 5:153-156.
55. Shen DD, Levy RH, Moor MJ, Savitch JL. (1990) Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Epilepsy Res 7:40-48.
56. Shen DD, Levy RH, Savitch JL, Boddy AV, Tombret F, Lepage F. (1992) Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol. Epilepsy Res 12:29-36.
57. Solaro C, Tanganelli P. (2004)Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol, Neurosurg Psychiatr 75:341.
58. Stephen LJ, Brodie MJ. (2002) Seizure-freedom with more than one antiepileptic drug. Seizure 11:349-351.
59. Stuchlik A, Kubova H, Mares P. (2001) Single systemic dose of vigabatrin induces early proconvulsant and later anticonvulsant effect in rats. Neurosci Lett 312:37-40.
60. Tallarida RJ. (2000) Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton.
61. Todorov AA, Kolchev CB, Todorov AB. (2005) Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 21:358-361.
62. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH. (1997) Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and In vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 62:490-504.
63. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J. (1986) Benzodiazepines impair and betacarbolines enhance performance in learning and memory tasks. Nature 321:864-866.
64. Wegmann R, Ilies A, Aurousseau M. (1978) Pharmaco-cellular enzymology of the mechanism of action of stiripentol in cardiazolinduced epilepsy. III. Protein, nucleoprotein, lipid, and proteoglycan metabolism. Cell Mol Biol Incl Cyto-Enzymol 23:455-480.
65. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. (2005) Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 3; doi:10.1002/14651858. CD001133.pub2. CD001133.